熊去氧胆酸联合非诺贝特治疗原发性胆汁性肝硬化患者临床疗效及对患者肝纤维化和肝功能影响

目的：探讨熊去氧胆酸联合非诺贝特治疗原发性胆汁性肝硬化患者临床疗效及对患者肝纤维化和肝功能影响。方法：选自我院于2013年6月~2015年6月期间收治的原发性胆汁性肝硬化患者72例依据随机数字表法分为观察组36例与对照组36例。对照组采用非诺贝特治疗,观察组在对照组基础上结合熊去氧胆酸治疗。两组疗程均为24周。比较两组治疗疗效,治疗前后肝功能和肝纤维化指标变化,及不良反应。结果：观察组治疗总有效率(97.22%)高于对照组(75.00%),且有统计学差异(P<0.05)；两组患者治疗后TBIL、AST及ALT水平降低,且有统计学差异(P<0.05)；观察组患者治疗后TBIL、AST及ALT水平低于对照组,且有统计学差异(P<0.05)；两组患者治疗后III型前胶原、IV胶原、HA及LN水平降低,且有统计学差异(P<0.05)；观察组患者治疗后III型前胶原、IV胶原、HA及LN水平低于对照组,且有统计学差异(P<0.05)；两组均未见明显不良反应。结论：熊去氧胆酸联合非诺贝特治疗原发性胆汁性肝硬化患者临床疗效显著,可改善肝纤维化和肝功能,具有重要临床研究价值。

Ursodeoxycholic acid combined with fenofibrate in the treatment of primary biliary cirrhosis in patients with clinical efficacy and effect on liver fibrosis and liver function in patients

Objective: To investigate the effect of ursodeoxycholic acid combined with fenofibrate in the treatment of primary biliary cirrhosis in patients with clinical efficacy and effect on liver fibrosis and liver function in patients. Methods: 72 patients with primary biliary cirrhosis admitted in our hospital from June 2013 ~ June 2015 were randomly divided into observation group (n=36) and control group (n=36). Control group with fenofibrate treatment, the observation group in the control group on the basis of ursodeoxycholic acid treatment. Two groups were treated for 24 weeks. The therapeutic effects of two groups were compared, the changes of liver function and hepatic fibrosis before and after treatment, and adverse reactions were observed. Results: the total efficiency of the observation group (97.22%) was higher than the control group (75.00%) (P<0.05); TBIL, AST and ALT decreased in two groups after treatment (P<0.05); TBIL, AST and ALT levels of observation group were lower than the control group after treatment (P<0.05); type III collagen, IV collagen, HA and LN decreased in two groups after treatment (P<0.05); observation of procollagen type III and IV collagen, HA and LN levels were lower than the control group after treatment,(P<0.05); there were no obvious adverse reaction. Conclusion: ursodeoxycholic acid combined with fenofibrate in the treatment of primary biliary cirrhosis in patients with clinical efficacy significantly, can improve hepatic fibrosis and liver function has important clinical value.